Blood Glucose Measurement Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Self-Glucose Measurement By Devices (Blood Glucose Meter, Blood Glucose Testing Strips, Lancets, Others) Continuous Glucose Measurement Devices) By End-User (Hospitals, Diagnostic Centres, Home Settings, Others) and Region Forecast 2020-2031

Blood Glucose Measurement Market size was valued at US$ 17.4 billion in 2024 and is expected to reach US$ 37.6 billion by 2031, growing at a significant CAGR of 10.1% from 2025-2031. Diabetes mellitus is a group of diseases that affects blood sugar (glucose) levels in the body. Glucose is very important for health as it's a vital energy source of the cells which is helpful to build the muscles and tissues. The market is one of the sources to fuel brain activities. Diabetes is characterized by increased levels of glucose in the blood. Blood glucose measuring devices help patients and healthcare professionals measure the glucose levels in the blood.

The market is driven by the high incidence of diabetes worldwide. According to the World Health Organisation (WHO), the prevalence of diabetes among adults about 18 years, old rose from 4.7% to 8.5% from 2012 to 2014 and diabetes is the 7^th leading cause of death. In addition to these factors, the rise in advancements in technology like the evolution of continuous glucose monitoring devices are boosting the growth of the market.

Moreover, the rise in demand for portable self-glucose measuring devices, the rise in investments and activities in R&D, and funds from the government in preventing and treating diabetes are boosting the growth of blood glucose measurement devices. Frequent product recalls of glucose testing strips owing to the manufactural defects and supply of test strips which are, less differentiated products among the self-blood glucose monitors are some of the factors that are hampering the growth of blood glucose measurement devices. Due to limited facilities of reimbursement and availability of alternative treatments which include cell-based assays, identification of biomarkers and artificial pancreas and high costs of the devices are the few threats for the growth of the market.

Key Developments

In July 2025, it was emphasized that maintaining blood sugar levels has become more crucial than ever. Whether for individuals with prediabetes, diabetes, or those aiming to lead a healthier lifestyle, continuous glucose monitoring plays a vital role in making informed and wise health decisions.

In July 2025, the Government of Newfoundland and Labrador, in collaboration with Newfoundland and Labrador Health Services, announced the expansion of its continuous glucose monitoring program to include individuals with gestational diabetes mellitus. This initiative builds on previous efforts, including the May expansion to cover all eligible individuals with Type 1 diabetes, based on medical and income-testing criteria. The program reflects the province’s commitment to enhancing diabetes care, supporting the Health Accord’s vision of improved health outcomes, and aligning with the goals of the National Diabetes Framework.

In July 2024, Roche announced that it had received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. This milestone enables the company to make the solution available to adults over the age of 18 living with type 1 and type 2 diabetes who are on flexible insulin therapy, marking an important step forward in expanding access to advanced diabetes management technologies.